Roche Oncology Turns In A Third Quarter To Rival The Good Old Days
Roche put up improved sales figures reflecting a 9% increase in oncology sales so far in 2012 and elaborated on its plan for continued growth in the face of eventual generic competition.
You may also be interested in...
Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.
Roche adjusted regulatory expectations for its pipeline during a third-quarter earnings call Oct. 16, moving up filing plans for onartuzumab (MetMAb) in metastatic non-small cell lung cancer to 2014 and pushing back an ocrelizumab filing in multiple sclerosis to 2015, both based on trial enrollment rates.
Two years after a painful restructuring to offset product setbacks and downward pressure on drug prices and three years after buying California-based biotech Genentech, Roche of Switzerland says it is fighting fit again, armed with a fully-laden pipeline and poised for new launches that increasingly focus on personalized health care.